Innospec vs Ingevity
Innospec reported revenue of $1.8 billion in fiscal 2025, 1.5 times Ingevity's $1.2 billion in fiscal 2025. Innospec's revenue fell 3.6% in its latest year, and Ingevity's fell 2.7%. Innospec had an operating margin of 7.3%, against 35.9% at Ingevity. Free cash flow was $88 million at Innospec and $274 million at Ingevity.
Side by side
| Innospec | Ingevity | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $1.8B | $1.2B |
| Revenue growth | −3.6% | −2.7% |
| Revenue growth a year, last 5 years | 8.3% | −0.8% |
| Gross margin | 27.7% | 39.5% |
| Operating margin | 7.3% | 35.9% |
| Net margin | 6.6% | −14.3% |
| Free cash flow | $88M | $274M |
| Free cash flow margin | 5.0% | 23.4% |
| Return on capital | 11.1% | 24.6% |
| Net debt to EBITDA | −1.7x | 2.1x |
| Dividends and buybacks | $66M | $56M |
| Change in diluted share count | −0.5% | −0.3% |
| Last close | $99.18 | $71.03 |
| P/E at the last close | 20.2× | 47.4× |
| Insider trades, last 12 months | bought $25,191, sold $398,854 | sold $1.8 million |
| Piotroski F-score | 6 of 9 | 6 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
InnospecIngevity
Operating margin
Percent of revenue
InnospecIngevity
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
InnospecIngevity
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Innospec and Ingevity pages.